Combination Chemotherapy in Treating Women With Breast Cancer Who Have Undergone Surgery
NCT00039546
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective in treating women after surgery for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of paclitaxel, epirubicin, and cyclophosphamide with or without gemcitabine in treating women who have undergone surgery for breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/06/2013
Locations: Queen Elizabeth Hospital at University of Birmingham, Birmingham, England +45 locations
Conditions: Breast Cancer
Register for Updates
Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer
NCT00070278
Unknown
RATIONALE: Drugs used in chemotherapy, such as epirubicin, cyclophosphamide, paclitaxel, and gemcitabine use different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy before surgery may shrink the tumor so that it can be removed during surgery. It is not yet known which combination chemotherapy regimen is more effective in treating early breast cancer. PURPOSE: This randomized phase III trial is studying different regimens of combination chemo... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
08/06/2013
Locations: Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust, Cambridge, England
Conditions: Breast Cancer
Register for Updates
Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer
NCT00022191
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective for urinary tract cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin plus gemcitabine with or without paclitaxel in treating patients who have stage IV urinary tract cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2013
Locations: Veterans Affairs Medical Center - Tucson, Tucson, Arizona +233 locations
Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Register for Updates
A Randomized, Multi-Center Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent Systems (GENESIS)
NCT00322569
Completed
To demonstrate non-inferiority in 6-month angiographic in-stent late lumen loss of the pimecrolimus-eluting coronary stent (Corio) compared to the CoStar coronary stent control arm and the dual pimecrolimus/paclitaxel-eluting (Symbio) coronary stent compared to the CoStar coronary stent control arm for the treatment of single de novo lesions \<25 mm in length in native coronary arteries 2.5 - 3.5 mm in diameter.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2013
Locations: Southampton University Hospital, Southampton, Not set
Conditions: Coronary Disease
Register for Updates
Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors
NCT00551122
Unknown
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, paclitaxel, ifosfamide, and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of gemcitabine when given together with paclitaxel, ifosfamide, and cisplatin, and to see how well they work in treating patients with progressive or relapsed m... Read More
Gender:
ALL
Ages:
Between 16 years and 60 years
Trial Updated:
01/22/2013
Locations: Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust, Birmingham, England +2 locations
Conditions: Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
Register for Updates
AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer
NCT00610714
Completed
The main purpose of this study is to determine if AZD0530 can improve the efficacy of standard chemotherapy for the treatment of ovarian cancer
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/14/2012
Locations: Research Site, Pleven, Not set +49 locations
Conditions: Ovarian Neoplasms, Ovarian Cancer
Register for Updates
Paclitaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Vulva
NCT00014599
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients who have locally advanced, metastatic, or recurrent cancer of the vulva.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/20/2012
Locations: Universitair Ziekenhuis Antwerpen, Edegem, Not set +13 locations
Conditions: Vulvar Cancer
Register for Updates
Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer
NCT00022620
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients who have refractory or recurrent endometrial cancer.
Gender:
FEMALE
Ages:
75 years and below
Trial Updated:
09/20/2012
Locations: Allgemeines Krankenhaus der Stadt Wien, Vienna, Not set +7 locations
Conditions: Endometrial Cancer
Register for Updates
Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx
NCT00025298
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. Giving chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy and radiation therapy. PURPOSE: Randomized phase II trial to compare the effectiveness of paclitaxel and carboplatin followed by c... Read More
Gender:
ALL
Ages:
Between 15 years and 70 years
Trial Updated:
09/20/2012
Locations: Institut Jules Bordet, Brussels, Not set +12 locations
Conditions: Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer, Oral Complications, Radiation Toxicity
Register for Updates
Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer
NCT00052312
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether doxorubicin and cisplatin are more effective with or without paclitaxel in treating endometrial cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of combining doxorubicin and cisplatin with or without paclitaxel in treating patients who have locally advanced, metastati... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/20/2012
Locations: Allgemeines Krankenhaus - Universitatskliniken, Vienna, Not set +34 locations
Conditions: Endometrial Cancer
Register for Updates
Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC
NCT00294762
Completed
This will be the first prospective study where patients will be selected on the basis of two measures of the epidermal growth factor receptor (EGFR) pathway. The study will assess prospectively the efficacy of erlotinib as a single agent or intercalated with chemotherapy in highly selected patients with EGFR overexpression and/or EGFR amplification.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2012
Locations: Central Hematology Oncology Medical Group Inc., Alhambra, California +42 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
ICON8: Weekly Chemotherapy in Ovarian Cancer
NCT01654146
Unknown
The purpose of this study is to determine if weekly chemotherapy (i.e. giving paclitaxel or carboplatin at a lower dose every week) is more effective than standard chemotherapy (paclitaxel and carboplatin given once every three weeks over 18 weeks) in treating ovarian cancer. The investigators also want to see if weekly chemotherapy causes more or fewer side-effects than standard chemotherapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/26/2012
Locations: Medical Research Council Clinical Trials Unit, London, Not set
Conditions: Ovarian Cancer
Register for Updates